Invivyd Inc

invivyd.com

What Do They Do?

Develops and commercializes antibody therapies to prevent and treat serious viral diseases, including coronavirus infections, for vulnerable patients.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

Healthcare providers, provider institutions and infusion centers buy PEMGARDA through specialty distributors; a small number buy directly from Invivyd. The product is shipped to sites of care, including clinics.

Do Revenues Turn Into Profits?

No. It lost $52.5M in FY2025.

Operating income, FY2025

−104% of revenue

▼ −69% (Loss) vs FY2024 (−$176.9M, −697%)

Net income, FY2025

−98% of revenue

▼ −69% (Loss) vs FY2024 (−$169.9M, −669%)

Free cash flow, FY2025

−109% of revenue

▼ −66% (Loss) vs FY2024 (−$170.6M, −672%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +21%; vs $11.8M in Q2 FY2025
Net income: ▲ +203% (Loss); vs −$14.7M in Q2 FY2025

Sep 1, 2026 Chair Marc Elia appointed CEO Marc Elia was appointed CEO, a role previously held by William Duke, who remains CFO.
Jul 24, 2026 Nasdaq notified Invivyd of a minimum-bid-price deficiency The company has until January 19, 2027 to regain compliance; otherwise its shares may become subject to delisting.
Jul 6, 2026 PEMGARDA received advance notice of EUA termination A press release announced advance notice of planned termination of PEMGARDA’s emergency use authorization.

Commercial product The older report describes its lead antibody as a candidate and discusses possible commercialization after authorization; the latest describes PEMGARDA as authorized and commercially launched, while another antibody advances through clinical trials.

Who Do They Compete With?

Competes with AstraZeneca, Roche Pharmaceuticals, Merck and, Pfizer Pharmaceuticals, Gilead, Genentech, Moderna, Pfizer-BioNTech, Novavax, GSK, and Sanofi

Comments